Felsch Robert Ora
Known title: See RemarksCIK: 0001917819
Felsch Robert Ora's purchase track record
Felsch Robert Ora has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/31/2022 | ARDX | $2K | +81.4% | +208.0% | -0.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| ARDX | ▼ Sell | Open Market | 3,567 | $21K | 8/20/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,485 | $27K | 5/21/2024 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 79,101 | $66K | 5/6/2024 | View on chart |
| ARDX | ▲ Buy | Option Exercise | 40,000 | $110K | 5/6/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 152,988 | $1.3M | 5/6/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 55,000 | $484K | 5/6/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 2,352 | $21K | 2/20/2024 | View on chart |
| ARDX | ▲ Buy | Grant | 70,120 | $0 | 1/16/2024 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,044 | $5K | 11/20/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,048 | $4K | 8/21/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 1,046 | $4K | 5/23/2023 | View on chart |
| ARDX | ▼ Sell | Open Market | 3,214 | $10K | 2/21/2023 | View on chart |
| ARDX | ▲ Buy | Grant | 26,000 | $0 | 1/5/2023 | View on chart |
| ARDX | ▲ Buy | Open Market | 3,000 | $2K | 8/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Ardelyx shares IBSRELA real-world data at ACG 2026
Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.
Ardelyx shares IBSRELA real-world data at ACG 2026. Ardelyx presented new real-world data at the ACG 2026 Annual Meeting showing that starting IBSRELA reduced healthcare resource use for patients with IBS-C. The company highlighted significant drops in GI-related medical visits and tests following treatment initiation. This clinical update adds to the evidence base for the drug's value in managing chronic gastrointestinal conditions.